Enlivex Ltd.’s SEC filings document its status as an Israeli foreign private issuer with ordinary shares listed under ENLV, its clinical-stage Allocetra™ program, and its prediction markets treasury strategy centered on the RAIN token and Rain protocol.
Recent Form 6-K reports furnish current disclosures on regulatory clearances for Allocetra™ in age-related knee osteoarthritis, annual financial results, tokenized representations of the company’s ordinary shares, Rain protocol ecosystem updates, senior secured convertible debt, and the completed corporate name change from Enlivex Therapeutics Ltd. to Enlivex Ltd. The filings also reference registration statements and governance records tied to shareholder approvals and capital structure.
Enlivex Ltd. (ENLV) reported that 135 of the 182 planned patients in its Phase 2b trial of Allocetra for moderate-to-severe age-related symptomatic primary knee osteoarthritis have been randomized and received the first injection. The trial is recruiting at sites in the United States, Denmark and Poland, and the company expects to report topline six-month data by mid-2027.
The global, multicenter study is randomized, double-blind and placebo-controlled, evaluating the efficacy and safety of intra-articular injections in patients aged 64 and older. Key efficacy endpoints compare changes from baseline in pain and function with placebo at three and six months; additional endpoints include quality-of-life measures and functional mobility assessments. The FDA granted RMAT designation for the population under study.
Enlivex Ltd. received a Nasdaq delisting notice stating that its ordinary shares did not meet the $1.00 minimum bid price requirement during the 30 consecutive business days before October 22, 2026. Because Enlivex effected a reverse split within the preceding 12 months, it is not entitled to a 180-day period to regain compliance.
Enlivex plans to appeal by timely requesting an oral hearing before the Nasdaq Hearings Panel. The request will stay any suspension or delisting action pending the hearing, and the shares will continue trading on the Nasdaq Capital Market during that time; Enlivex cannot assure the appeal will succeed or that the shares will continue trading there afterward. Enlivex also announced a 1-for-16 reverse split of its ordinary shares, effective October 27, 2026.
After shareholder approval, Enlivex Ltd.'s board selected a 1-for-16 reverse share split; ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market on October 27, 2026. Authorized ordinary shares will decrease from 158,333,333 to 9,895,833, while par value will increase from NIS 6.00 to NIS 96.00 per share. Issued and outstanding ordinary shares will decline from 24,511,905 to approximately 1,531,995, subject to fractional-share rounding.
Outstanding warrants and options will have proportionate adjustments to their exercise prices and the shares issuable upon exercise. The split will not affect ownership percentages, except for adjustments from fractional-share rounding, or modify voting rights.
Enlivex Ltd. (ENLV) announced a cost reduction plan effective immediately, designed to substantially reduce cash burn and focus resources on its Phase 2b trial of Allocetra™ for age-related primary knee osteoarthritis. The measures include winding down non-clinical R&D, reducing the workforce, and substantial salary reductions for management, including Chief Executive Officer Dr. Oren Hershkovitz.
The company expects topline six-month data by mid-2027. Its global, multicenter Phase 2b trial is randomized, double-blind and placebo-controlled, and evaluates intra-articular Allocetra™ in patients aged 64 and older with moderate-to-severe age-related symptomatic primary knee OA. Enlivex says its completed Phase 1/2a trial showed statistically significant and clinically meaningful improvements in knee pain and function versus placebo at three and six months, with a favorable safety profile.
Enlivex Ltd. revised its extraordinary-meeting materials, moving the meeting to October 16, 2026 and the record date to October 5, 2026. Shareholders will consider a first reverse share split at a ratio from 1-for-13 to 1-for-16, effective as soon as practicable after approval, with the Board choosing the final ratio. They will also vote on authority for one or more additional reverse splits, at an aggregate ratio from 1-for-2 to 1-for-1,000, if implemented within 12 months after the meeting.
The company says its ordinary shares closed below Nasdaq’s $1.00 minimum bid price each trading day since September 10, 2026. If the price remains below $1.00 for 30 consecutive trading days through October 21, 2026, Nasdaq will issue a Staff delisting determination; the company says it would not qualify for a 180-day compliance period. The Board recommends voting FOR; approval requires a majority of shares represented and voting, excluding abstentions.
Enlivex Ltd. changed the record date for its October 14, 2026 extraordinary general meeting to October 1, 2026, replacing October 5, 2026. Shareholders will consider a 1-for-16 reverse share split and a related amendment to the Articles of Association; if approved, the split would take effect as soon as possible following shareholder approval.
Enlivex says the proposal is intended to address Nasdaq’s $1.00 minimum bid-price requirement. Its ordinary shares closed below that level each trading day from September 10 through September 29, 2026. If the bid price remains below $1.00 for 30 consecutive trading days, through October 21, 2026, Nasdaq will issue a Staff delisting determination. Approval requires a majority of shares represented and voting, excluding abstentions; the board unanimously recommends voting FOR.
Enlivex Ltd. is asking shareholders to approve a 1-for-16 reverse split of its ordinary shares and a related amendment to its Articles of Association. If approved, the split would take effect as soon as possible after shareholder approval. The vote is scheduled for October 14, 2026; approval requires a majority of ordinary shares represented and voting on the proposal, excluding abstentions. Enlivex says the proposal is intended to address Nasdaq’s $1.00 minimum bid-price requirement. Its shares closed below $1.00 each trading day from September 10 through September 29, 2026. If the bid remains below $1.00 for 30 consecutive trading days through October 21, Nasdaq will issue a staff delisting determination; Enlivex would not be entitled to a 180-day compliance period. The proposal also provides for fractional shares to be rounded up to the nearest whole share. The proxy describes potential U.S. tax consequences if Enlivex is treated as a passive foreign investment company.
Enlivex Ltd. (ENLV) reported six-month net income of $1,949.047 million for the period ended June 30, 2026, versus a $5.320 million net loss a year earlier. It had no operating revenue. The company reported $609.763 million of income on digital assets, net, and a $1,943.680 million gain from changes in the RAIN Option’s fair value; it described aggregate gains of $2.55 billion as unrealized and non-cash. Operating loss was $15.828 million, compared with $6.611 million.
At June 30, 2026, digital assets had a fair value of $1,254.136 million and the RAIN Option $3,634.737 million. Together they represented a substantial majority of total assets, exposing results and financial position to RAIN price volatility. Operating cash used was $10.935 million, versus $5.822 million a year earlier; cash and cash equivalents were $5.518 million.
Enlivex issued a senior secured convertible note with a $21 million face value for approximately $19 million in gross proceeds, due March 23, 2027. It completed a 1-for-15 reverse share split effective July 9, 2026, and later reported regaining Nasdaq minimum-bid-price compliance.
Enlivex Ltd. (ENLV) reports that it has terminated a previously announced securities purchase agreement with the Rain Foundation under which it had agreed, subject to shareholder approval, to sell and issue 66,666,667 ordinary shares in a private placement payable in RAIN tokens. The agreement was terminated in accordance with Enlivex’s contractual termination rights, so the company will not complete this token-funded private placement or seek shareholder approval for it. Enlivex reiterates that it is a “quality longevity” company advancing its Allocetra™ immunotherapy program for age-related osteoarthritis and operating a prediction markets treasury strategy built around the Rain protocol.
Enlivex Ltd. is registering for resale up to 10,000,000 ordinary shares that may be sold from time to time by the holder of its Senior Secured Convertible Promissory Note, without Enlivex receiving any proceeds from these sales. The shares are issuable under a $21.0 million note issued in a March 23, 2026 private placement for an aggregate purchase price of $19.0 million. The note matures on March 23, 2027, is senior secured, does not bear interest unless in default when a 10.0% annual rate applies, and is repayable in nine monthly principal installments of approximately $2.3 million, in cash, shares, or a combination. The note is convertible at an initial price of $40.37625 per share and may be prepaid at 105% of outstanding principal or, upon certain events of default, be put back to Enlivex at 110% of outstanding principal. Enlivex’s ordinary shares trade on the Nasdaq Capital Market under the symbol ENLV, with 17,485,462 shares outstanding as of August 5, 2026, and a last reported price of $1.84 per share on August 12, 2026.